σ2 Receptors: Regulation of cell growth and implications for cancer diagnosis and therapeutics

Sigma Receptors: Chemistry, Cell Biology and Clinical Implications

Volumn , Issue , 2007, Pages 215-235

  Bowen, Wayne D ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 53649101273     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-36514-5_11     Document Type: Chapter

References (99)

1. Walker JM, Bowen WD, Walker FO, Matsumoto RR, de Costa BR, Rice KC. Sigma receptors: Biology and function. Pharmacol Rev 1990, 42:355-402.
2. Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio JM, Rothma RB, Su TP, Tarn SW, Taylor DP. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 1992, 13: 85-86.
3. Bowen WD. Biochemical pharmacology of sigma receptors, in: Aspects of Synaptic Transmission Vol. II: Acetylcholine, Sigma Receptors, CCK and Eicosanoids, Neurotoxins. (T.W. Stone, ed.), Taylor and Francis, London, U.K., 1993, pp. 113-136.
4. Bowen WD. Sigma receptors: Recent advances and new clinical potentials. Pharmaceutica Acta Helvetiae 2000, 74: 211-218.
5. Su TP, Hayashi T. Understanding the molecular mechanism of sigma-1 receptors: Towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 2003, 10:2073-2080.
6. Guitart X, Codony X, Monroy X. Sigma receptors: biology and therapeutic potential. Psychopharmacology 2004, 174: 301-319.
7. Maurice T. Neurosteroids and sigma-1 receptors, biochemical and behavioral relevance. Pharmacopsychiatry 2004, 37(Suppl 3): S171-S182.
8. Hellewell SB, Bowen WD. A sigma-like binding site in rat pheochromocytoma (PC12) cells: Decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that in guinea pig brain. Brain Res 1990, 527:244-253.
9. Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, Glossmann H. Purification, molecular cloning, and expression of the mammalian sigmarbinding site. Proc Natl Acad Sci USA 1996, 93: 8072-8077.
10. Prasad PD, Li HW, Fei YJ, Ganapathy ME, Fujita T, Plumley LH, Yang-Feng TL, Leibach FH, Ganapathy V. Exon-intron structure, analysis of promoter region, and chromosomal localization of the human type 1 sigma receptor gene. J Neurochem 1998, 70:443-451.
11. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors: Characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol Mol Pharmacol Sect 1994, 268: 9-18.
12. Su, TP, London, ED, Jaffe, JH. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 1988, 240:219-221.
13. Patterson TA, Connor M, Chavkin C. Recent evidence for endogenous substance(s) for sigma receptors, in: The Sigma Receptors, Neuroscience Perspectives Series. (Y. Itzhak, ed.), Academic Press, London, 171-189, 1994.
14. 3H](+)-Pentazocine: A potent and highly selective benzomorphan-based probe for sigma-1 receptors. Mol Neuropharmacol 1993, 3:117-126.
15. Wolfe Jr SA, Culp SG, De Souza EB. Sigma receptors in endocrine organs: Identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. Endocrinology 1989, 124:1160-1172.
16. Thomas GE, Szucs M., Mamone JY, Bern WT, Rush MD, Johnson FE, Coscia CJ. Sigma and opioid receptors in human brain tumors. Life Sci 1990, 46:1279-1286.
17. Bern WT, Thomas GE, Mamone JY, Homan SM, Levy BK, Johnson FE, Coscia CJ. Overexpression of sigma receptors in nonneural human tumors. Cancer Res 1990, 51:6558-6562.
18. John CS, Vilner BJ, Schwartz AM, Bowen WD. Characterization of sigma receptor binding sites in human biopsied solid breast tumors. J Nucl Med 1996, 37:267P.
19. Vilner BJ, Bowen WD. Characterization of sigma-like binding sites of NB41 A3, S-20Y, and N1E-115 neuroblastomas, C6 glioma, and NG108-15 neuroblastoma-glioma hybrid cells: Further evidence for sigma-2 receptors. In: Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection? J.-M. Kamenka and E.F. Domino, eds. NPP Books, Ann Arbor, MI, 1992, pp. 341-353.
20. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995, 55:408-413.
21. Ganapathy ME, Prasad PD, Huang W, Seth P, Leibach FH, Ganapathy V. Molecular and ligand-binding characterization of the sigma-receptor in the Jurkat human T lymphocyte cell line. J Pharmacol Exp Ther 1999, 289:251-260.
22. Mach RH, Smith CR, al-Nabulsi I, Whirrett BR, Childers SR, Wheeler KT. Sigma-2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res 1997, 57:156-161.
23. Al-Nalbusi I, Mach RH, Wang LM, Wallen CA, Keng PC, Sten K, Childers SR, Wheeler KT. Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumor cells. British J Cancer 1999, 81:925-933.
24. Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC, Mach RH. Sigma-2 receptors as a biomarker of proliferation in solid tumors. Br J Cancer 2000, 82:1223-1232.
25. Vilner BJ, de Costa BR, Bowen WD. Cytotoxic effects of sigma ligands: Sigma receptor-mediated alterations in cellular morphology and viability. J Neurosci 1995, 15:117-134.
26. de Costa BR, Radesca L, Di Paolo L, Bowen WD. Synthesis, characterization and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(l- pyrrolidinyl)ethylamines: Structural requirements and binding affinity at the sigma receptor. J Med Chem 1992, 35:38-47.
27. Bowen WD, Walker JM, de Costa BR, Wu R, Tolentino PJ, Finn D, Rothman RB, Rice KC. Characterization of the enantiomers of cis-N-[2-(3, 4-dichlorophenyl)ethyl]-N- methyl-2-(l-pyrrolidinyl)cyclohexylamine (BD737 and BD738): Novel compounds with high affinity, selectivity, and biological efficacy at sigma receptors. J Pharmacol Exp Ther 1992, 262:32-40.
28. Vilner BJ, Bowen WD. Sigma-2 receptor agonists induce apoptosis in rat cerebellar granule cells and human SK-N-SH neuroblastoma cells. Soc Neurosci Abst 1997, 23:2319, #905.6.
29. Bowen WD, Vilner BJ, Williams W, Bandarage UK, Kuehne ME. Novel ibogaine analogs as selective sigma-2 receptor probes: Ligand binding and functional assays. Soc Neurosci Abst 1997, 23:2319, #905.7.
30. Bowen WD. Sigma receptors and iboga alkaloids. Alkaloids Chem Biol 2001, 56:173-191.
31. Bertha CM, Vilner BJ, Mattson MV, Bowen WD, Becketts K, Xu H, Rothman RB, Flippen-Anderson JL, Rice KC. (E)-8 Benzylidene derivatives of 2-methyl-5-(3- hydroxyphenyl)morphans: Highly selective ligands for the sigma-2 receptor subtype. J Med Chem 1995, 38:4776-4785.
32. Bowen WD, Bertha CM, Vilner BJ, Rice KC. CB-64D and CB-184: Ligands with high sigma-2 receptor affinity and subtype selectivity. Eur J Pharmacol 1995, 278:257-260.
33. Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 2002, 62:313-322.
34. Brent PJ, Pang GT. Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur J Pharmacol 1995, 278:151-160.
35. i in colon and mammary adenocarcinoma cells. Biochem Biophys Res Commun 1996, 219:219-226.
36. Casellas P, Galiegue S, Bourrrie B, Ferrini JB, Jbilo O, Vidal H. SR31747A: A peripheral sigma ligand with potent antitumor activities. Anticancer Drugs 2004, 15:113-118.
37. + channel inhibition and p27kipl accumulation. J Pharmacol Exp Ther 2004, 311:1105-1114.
38. Colabufo NA, Berardi F, Contino M, Niso M, Abate C, Perrone R, Tortorella V. Antiproliferative and cytotoxic effects of some sigma2 agonists and sigma, antagonists in tumor cell lines. Naunyn Schmiedeberg Arch Pharmacol 2004, 370: 106-113.
39. Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MV, O'Neill M, Howie J, Samson J, Watt S, Murray K, McLean D, Leslie NR, Safrany ST, Ferguson MJ, Peters JA, Prescott AR, Box G, Hayes A, Nutley B, Raynaud F, Downes CP, Lambert JJ, Thompson AM, Eccles S. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res 2004, 64:4875-4886.
40. Aydar E, Palmer CP, Djamgoz MB. Sigma receptors and cancer: possible involvement of ion channels. Cancer Res 2004, 64:5029-5035.
41. Berridge MJ, Bootman MD Lipp P. Calcium - A life and death signal. Nature 1998, 395:645-648.
42. McConkey DJ, Orrenius S. The role of calcium in the regulation of apoptosis. J Leuk Biol 1996, 59:775-783.
43. Khal CR, Means AR. Regulation of cell cycle progression by calcium/calmodulin- dependent pathways. Endocrine Rev 2003, 24:719-736.
44. Demaurex N, Distelhorst C. Apoptosis - The calcium connection. Science 2003, 300:65-67.
45. Vilner BJ, Bowen WD. Modulation of cellular calcium by sigma-2 receptors: Release from intracellular stores in human SK-N-SH neuroblastoma cells. J Pharmacol Exp Ther 2000, 292:900-911.
46. Vilner BJ, Bowen WD. Relationship of sigma-2 receptor-mediated increases in intracellular calcium to induction of morphological changes and apoptosis in human SK- N-SH neuroblastoma cells. Soc Neurosci Abst 1998, 24:1594, #627.6.
47. Kolesnick RN, Kronke M. Regulation of ceramide production and apoptosis. Ann Rev Physiol 1998, 60:643-665.
48. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004, 4:604-616.
49. Obeid LM, Hannun YA. Ceramide: A stress signal and mediator of growth suppression and apoptosis. J Cell Biochem 1995, 58:191-198.
50. Galardi S, Kishikawa K, Kamibayashi C, Mumby MC, Hannun YA. Purification and characterization of ceramide-activated protein phosphatases. Biochem 1998. 37:11232-11238.
51. Chalfant CE, Kishikawa K, Bielawska A, Hannun YA. Analysis of ceramide-activated protein phosphatases. Methods Enzymol 2000, 312:420-428.
52. Zinda MJ, Vlahos CJ, Lai MT. Ceramide induces the dephosphosphorylation and inhibition of constitutively activated Akt in PTEN negative U87mg cells. Biochem Biophys Res Commun 2001, 280:1107-1115.
53. Ruvolo PP, Clark W, Mumby M., Gao F, May WS. A functional role for the B56 α-subunit of protein phosphatases 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function. J Biol Chem 2002, 277:22847-22852.
54. 2+-independent sphingomyelinase activities precede commitment to apoptosis and are not a consequence of caspase-3-like activity in Molt-4 cells in response to thymidylate synthase inhibition by GW1843. Blood 1998, 91:4350-4360.
55. Mathiasen IS, Lademann U, Jaattela M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by bcl-2 but does not involve known caspases or p53. Cancer Res 1999, 59:4848-4856.
56. Crawford KW, Coop A, Bowen WD. Sigma-2 receptors regulate changes in sphingolipid levels in breast tumor cells. Eur J Pharmacol 2002, 443:207-209.
57. Bowen WD, Crawford KW, Huang S, Walker JW. Activation of sigma-2 receptors causes changes in ceramide levels in neuronal and non-neuronal cell lines. Soc Neurosci Abst 2000, 26:601, #226.11.
58. Bowen WD, Crawford KW, Coop A. Sigma-2 receptors may activate sphingolipid- ceramide N-deacylase (SCDase) as a mechanism to regulate cell growth. Soc Neurosci Abst 2001, 27:948, #364.1.
59. Ito M, Kurita T, Kita K. A novel enzyme that cleaves the N-acyl linkage of ceramides in various glycosphingolipids as well as sphingomyelin to produce their lyso forms. J Biol Chem 1995, 270:24370-24374.
60. Kita K, Kurita T, Ito M. Characterization of the reversible nature of the reaction catalyzed by sphingolipid ceramide N-deacylase: A novel form of reverse hydrolysis reaction. Eur J Biochem 2001, 268:592-602.
61. Stoica BA, Movsesyan VA, Lea PM 4th, Faden AI. Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3beta, and induction of the mitochondrial-dependent intrinsic caspase pathway. Mol Cell Neurosci 2003, 22:365-382.
62. Spiegel S, Culliver O, Edsall LC, Kohama T, Menzeleev R, Olah Z, Olivera, A, Pirianov, G, Thomas DM, Tu Z, Van Brocklyn JR, Wang F. Sphingosine-1-phosphate in cell growth and cell death. Ann NY Acad Sci 1998, 845:11-18.
63. Spiegel S, Milstien S. Functions of a new family of sphingosine-1-phosphate receptors. Biochim Biophys Acta 2000, 1484:107-116.
64. Myerzu Heringdorf D, van Koppen CJ, Jakobs KH. Molecular diversity of sphingolipid signalling. FEBS Lett 1997, 410:34-38.
65. Xu Y. Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal transduction. Biochim Biophys Acta 2002, 1582:81-88.
66. Meyerzu Heringdorf D, Himmel HM, Jakobs KH. Sphingosylphosphorylcholine- biological functions and mechanisms of action. Biochim Biophys Acta 2002, 1582:178-189.
67. 2+ release-mediating protein from endoplasmic reticulum. Proc Natl Acad Sci USA 1996, 93:1993-1996.
68. Stein WD, Bates SE, Fojo T. Intractable cancers: The many faces of multidrug resistance and the many targets it presents for therapeutic attack. Curr Drug Targets 2004, 5:333-346.
69. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005, 205:275-292.
70. Mathiasen IS, Jaattela M. Triggering caspase-independent cell death to combat cancer. Trends Mol Med 2002, 8:212-220.
71. Broker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: A review. Clin Cancer Res 2005, 11:3155-3162.
72. Selivanova G. Mutant p53: The loaded gun. Curr Opin Investig Drugs 2001, 2:1136-1141.
73. Gasco M, Crook T. p53 members and chemoresistance in cancer: What we know and what we need to know. Drug Resist Update 2003, 6:323-328.
74. Ryan KM, Vousden KH. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 1998, 18:3692-3698.
75. Wallace-Brodeur RR, Lowe SW. Clinical implications of p53 mutations. Cell Mol Life Sci 1999, 55:64-75.
76. Cohen GM. Caspases. The executioners of apoptosis. Biochem J 1997, 326:1-16.
77. Prokop A, Wieder T, Sturm I, Essmann F, Seeger K, Wuchter C, Ludwig WD, Henze G, Dorken B, Daniel PT. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 2000, 14:1606-1613.
78. Teitz T, Lahti JM, Kidd VJ. Aggressive childhood neuroblastomas do not express caspase-8: An important component of programmed cell death. J Mol Med 2001, 79:428-436.
79. Baumler C, Duan F, Onel K, Rapaport B, Jahnwar S, Offit K, Elkon KB. Differential recruitment of caspase 8 to cFlip confers sensitivity or resistance to Fas-mediated apoptosis in a subset of familial lymphoma patients. Leuk Res 2003, 27:841-851.
80. Linn SC, Honkoop AH, Hoekman K, van der Valk P, Pinedo HM, Giaccone G. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996, 74:63-68.
81. Bowen WD, Jin B, Blann E, Vilner BJ, Lyn-Cook BD. Sigma receptor ligands modulate expression of the multidrug resistance gene in human and rodent brain tumor cell lines. Proc Am Assoc Cancer Res 1997, 38:479, #3206.
82. John CS, Bowen WD, Saga T, Kinuya S, Vilner BJ, Baumgold J, Paik CH, Reba RC, Neumann RD, Varma VM, McAfee JG. A malignant melanoma imaging agent: Synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2- piperidinylaminoethyl)4-iodobenzamide. J Nucl Med 1993, 34:2169-2175.
83. 125l]N-(2- Piperidinylaminoethyl)4-iodobenzamide and related analogs as sigma receptor imaging agents: High affinity binding to human malignant melanoma and rat C6 glioma cell lines. J Labelled Compd Radiopharm 1994, 33:242-244.
84. 125I]BP: A high affinity sigma receptor ligand for potential imaging of breast cancer. Cancer Res 1995, 55:3022-3027.
85. 18F] labeled benzamides: High affinity sigma receptor ligands for PET imaging. Nucl Med Biol 1997, 24:333-340.
86. 125I]BP: A potential sigma receptor marker for human prostate tumors. Nucl Med Biol 1998, 25:189-194.
87. John CS, Bowen WD, Fisher SJ, Lim BB, Geyer BC, Vilner BJ, Wahl RL. Synthesis, in vitro pharmacologic characterization, and preclinical evaluation of N-[2-(l'- piperidinyl)ethyl]-3-[125I]iodo-4-methoxybenzamide (P[125I]MBA) for imaging breast cancer. Nucl Med Biol 1999, 26:377-382.
88. John CS, Vilner BJ, Geyer BC, Moody T, Bowen WD. Targeting sigma receptor- binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors. Cancer Res 1999, 59:4578-4583.
89. 125I]N-[2-(4-iodophenyl)ethyl]-N-methyl-2-( 1 - piperidinyl)ethylamine: A high affinity ligand for imaging sigma receptor positive tumors. Nucl Med Biol 1996, 23:761-766.
90. John CS, Lim BB, Vilner BJ, Bowen WD. Substituted N-(9-benzyl)-N-methyl-2-(l'- piperidinyl)ethylamine (BME) and its analogs as new sigma receptor markers: Synthesis, characterization, and in vivo evaluation. J Labelled Compd Radiopharm 1999, 42(Suppl 1 ):S411-S413.
91. 11C-SA4503: A feasibility study. J Nucl Med 2004, 45:1939-1945.
92. John CS, Lim BB, Vilner BJ, Geyer BC, Bowen WD. Substituted halogenated arylsulfonamides: A new class of sigma receptor binding tumor imaging agents. J Med Chem 1998, 41:2445-2450.
93. John CS, Lim BB, Geyer BC, Vilner BJ, Bowen WD. 99mTc-Labeled sigma-receptor- binding complex: Synthesis, characterization, and specific binding to human ductal breast carcinoma (T47D) cells. Bioconjugate Chem 1997, 8:304-309.
94. Caveliers V, Everaert H, John CS, Lahoutte T, Bossuyt A. Sigma receptor scintigraphy with N-[2-(r-piperidinyl)ethyl]-3-(123)I-iodo-4-methoxybenzamide of patients with suspected primary breast cancer: First clinical results. J Nucl Med 2002, 43:1647-1649.
95. Michelot JM, Moreau MF, Veyre AJ, Bonafous JF, Bacin FJ, Madelmont JC, Bussiere F, Souteyrand PA, Mauclaire LP, Chossat FM, et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4- iodobenzamide). J Nucl Med 1993, 34:1260-1266.
96. Nicholl C, Mohammed A, Hull WE, Bubeck B, Eisenhut M. Pharmacokinetics of iodine-123-1MBA for melanoma imaging. J Nucl Med 1997, 38:127-133.
97. 125I]IUDR. Nucl Med Biol 2001, 28:451-458.
98. Choi SR, Yang B, Plossl K, Chumpradit S, Wey SP, Acton PD, Wheeler K, Mach RH, Kung HF. Development of a Tc-99m labeled sigma-2 receptor-specific ligand as a potential breast tumor imaging agent. Nucl Med Biol 2001, 28:657-666.
99. 2 receptor ligands. Bioorg Med Chem Lett 2004, 14:195-202.